The Latest from OHSU Knight Cancer Institute
The OHSU Knight Cancer Institute is an international leader in cancer research and personalized treatment. The institute's director, Brian Druker, M.D., helped usher in the era of personalized cancer medicine with his discovery that cancer cells could be shut down by disabling the molecules that drive their growth without harming healthy cells. The drug that resulted from that research, Gleevec®, revolutionized how cancer is treated. It also inspired a new wave of exploration of treatments that target cancer-causing molecules.
Ending Cancer As We Know It
With the mission of ending cancer as we know it, the OHSU Knight Cancer Institute continues to build its scientific and clinical leadership and cancer treatment resources. Public support and private philanthropy – including a transformative $100 million gift from Nike Chairman Phil Knight and his wife Penny in 2008 – have provided crucial resources to advance our progress.
We provide a range of cancer treatment services, including the most advanced treatments available for many types of cancer. We also support a team of world-class scientists focused on cancer research. The OHSU Knight Cancer Institute offers:
- Comprehensive inpatient and outpatient cancer treatment options (medical, surgical and radiation oncology)
- More than 400 clinical trials, including participation in national research studies
- Outreach programs from community partnerships to national legislative advocacy focused on cancer prevention and treatment
- Collaboration with organizations, from local to national <link to new collaborating with technology leaders page>, to share resources and expertise